Compare Merck & Co., Inc. (MRK) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Vipshop Holdings Ltd - ADR — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Vipshop Holdings Ltd - ADR trades at $12.52 (market cap $6.20B). The key difference: Merck & Co., Inc. is far larger — about 59.1× Vipshop Holdings Ltd - ADR's market cap, and Vipshop Holdings Ltd - ADR pays the higher dividend (4.76%). Which is the better fit depends on your goals.
| MRK | VIPS | |
|---|---|---|
Market Cap | $366.28B | $6.20B |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $20.68 |
52-Week Low | $77.60 | $12.51 |
Enterprise Value | $413.04B | $3.02B |
Dividend Yield | 2.29% | 4.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $156.71. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending, and maintains a robust gross profit margin of 72.97%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.
The outlook for MRK is positive, driven by earnings momentum and strategic acquisitions, but risks include high valuation multiples like a P/E of 118.77 and regulatory pressures. Investors should weigh the company's solid cash flow and analyst support against potential market volatility and integration challenges from recent M&A activity.
Vipshop Holdings trades at $13.03, down 1.29% with bearish technical signals despite attractive valuation metrics including a P/E of 4.21 and P/S of 0.41. Recent earnings showed mixed results with Q2 2026 missing expectations, while revenue has declined from $112.9B in 2023 to $105.9B in 2025. The company maintains strong profitability with 9.82% net margin and robust cash flow generation.
Analyst consensus remains positive with 54% buy ratings, though near-term headwinds from consumer spending caution and competitive pressures create uncertainty. The stock's deep value proposition is balanced against growth challenges, requiring careful monitoring of Q3 2026 earnings results for directional clarity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Vipshop Holdings Ltd - ADR
Vipshop Holdings Ltd is an online discount retailer for brands in China. The company offers branded products to consumers in China through flash sales on its vipshop.com, vip.com and lefeng.com websites. Flash sales represent an online retail format combining the advantages of e-commerce and discount sales through selling a finite quantity of discounted products or services online for a limited period of time. It deals in a wide range of products and services for consumers specializing in branded cosmetics, apparel, healthcare products, food and other consumer products. Its operating segment includes Vip.com and Shan Shan Outlets. The company generates maximum revenue from Vip.com segment.
Read more on VIPS →
